

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 84

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|--------|
| 1990 | 1991 | 1992 | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | 2051 | 2052 | 2053 | 2054 | 2055 | 2056 | 2057 | 2058 | 2059 | 2060 | 2061 | 2062 | 2063 | 2064 | 2065 | 2066 | 2067 | 2068 | 2069 | 2070 | 2071 | 2072 | 2073 | 2074 | 2075 | 2076 | 2077 | 2078 | 2079 | 2080 | 2081 | 2082 | 2083 | 2084 | 2085 | 2086 | 2087 | 2088 | 2089 | 2090 | 2091 | 2092 | 2093 | 2094 | 2095 | 2096 | 2097 | 2098 | 2099 | 2100 | 2101 | 2102 | 2103 | 2104 | 2105 | 2106 | 2107 | 2108 | 2109 | 2110 | 2111 | 2112 | 2113 | 2114 | 2115 | 2116 | 2117 | 2118 | 2119 | 2120 | 2121 | 2122 | 2123 | 2124 | 2125 | 2126 | 2127 | 2128 | 2129 | 2130 | 2131 | 2132 | 2133 | 2134 | 2135 | 2136 | 2137 | 2138 | 2139 | 2140 | 2141 | 2142 | 2143 | 2144 | 2145 | 2146 | 2147 | 2148 | 2149 | 2150 | 2151 | 2152 | 2153 | 2154 | 2155 | 2156 | 2157 | 2158 | 2159 | 2160 | 2161 | 2162 | 2163 | 2164 | 2165 | 2166 | 2167 | 2168 | 2169 | 2170 | 2171 | 2172 | 2173 | 2174 | 2175 | 2176 | 2177 | 2178 | 2179 | 2180 | 2181 | 2182 | 2183 | 2184 | 2185 | 2186 | 2187 | 2188 | 2189 | 2190 | 2191 | 2192 | 2193 | 2194 | 2195 | 2196 | 2197 | 2198 | 2199 | 2200 | 2201 | 2202 | 2203 | 2204 | 2205 | 2206 | 2207 | 2208 | 2209 | 2210 | 2211 | 2212 | 2213 | 2214 | 2215 | 2216 | 2217 | 2218 | 2219 | 2220 | 2221 | 2222 | 2223 | 2224 | 2225 | 2226 | 2227 | 2228 | 2229 | 2230 | 2231 | 2232 | 2233 | 2234 | 2235 | 2236 | 2237 | 2238 | 2239 | 2240 | 2241 | 2242 | 2243 | 2244 | 2245 | 2246 | 2247 | 2248 | 2249 | 2250 | 2251 | 2252 | 2253 | 2254 | 2255 | 2256 | 2257 | 2258 | 2259 | 2260 | 2261 | 2262 | 2263 | 2264 | 2265 | 2266 | 2267 | 2268 | 2269 | 2270 | 2271 | 2272 | 2273 | 2274 | 2275 | 2276 | 2277 | 2278 | 2279 | 2280 | 2281 | 2282 | 2283 | 2284 | 2285 | 2286 | 2287 | 2288 | 2289 | 2290 | 2291 | 2292 | 2293 | 2294 | 2295 | 2296 | 2297 | 2298 | 2299 | 2300 | 2301 | 2302 | 2303 | 2304 | 2305 | 2306 | 2307 | 2308 | 2309 | 2310 | 2311 | 2312 | 2313 | 2314 | 2315 | 2316 | 2317 | 2318 | 2319 | 2320 | 2321 | 2322 | 2323 | 2324 | 2325 | 2326 | 2327 | 2328 | 2329 | 2330 | 2331 | 2332 | 2333 | 2334 | 2335 | 2336 | 2337 | 2338 | 2339 | 2340 | 2341 | 2342 | 2343 | 2344 | 2345 | 2346 | 2347 | 2348 | 2349 | 2350 | 2351 | 2352 | 2353 | 2354 | 2355 | 2356 | 2357 | 2358 | 2359 | 2360 | 2361 | 2362 | 2363 | 2364 | 2365 | 2366 | 2367 | 2368 | 2369 | 2370 | 2371 | 2372 | 2373 | 2374 | 2375 | 2376 | 2377 | 2378 | 2379 | 2380 | 2381 | 2382 | 2383 | 2384 | 2385 | 2386 | 2387 | 2388 | 2389 | 2390 | 2391 | 2392 | 2393 | 2394 | 2395 | 2396 | 2397 | 2398</ |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|--------|

Registered Company Number 1107468

1. The 1992-1993 season was a particularly dry one, with only 10.5 inches of rain falling in the area. This was a significant factor in the low water levels observed in the reservoirs. The lack of rainfall led to a rapid depletion of the water supply, which was not replenished by the usual annual rains. This situation was exacerbated by the fact that the reservoirs were already at low levels at the start of the season. The combination of these factors led to a severe shortage of water, which had a significant impact on the local population and the environment. The government and the local authorities were forced to take emergency measures to ensure that the population had access to water. These measures included the construction of temporary water supply systems and the distribution of water from other sources. The situation was a stark reminder of the importance of water management and the need for sustainable water resources. The government and the local authorities must take steps to ensure that the water supply is secure for the future. This can be achieved by investing in water infrastructure, such as dams and reservoirs, and by implementing water conservation measures. The local population must also be educated about the importance of water and the need to conserve it. Only by taking these steps can we ensure that we have a secure water supply for the future.

TILBURY ESTATES LIMITED

Report and Unaudited Financial Statements

31 December 2020

...and the fact that the *Journal* is a journal of the American Psychological Association, the largest and most influential of the professional organizations in the field of psychology, is a source of great strength and authority.

1. *Chlorophyll a* and *Chlorophyll b* were determined by the method of Arar and Collins (1971).

1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 26

1234

2011年12月15日 星期三

1. *Pharmaceutical industry*—United States—History.
 2. *Pharmaceutical industry*—United States—Economic aspects.
 3. *Pharmaceutical industry*—United States—Government relations.
 4. *Pharmaceutical industry*—United States—Social aspects.
 5. *Pharmaceutical industry*—United States—Research and development.
 6. *Pharmaceutical industry*—United States—Marketing.
 7. *Pharmaceutical industry*—United States—Regulation.
 8. *Pharmaceutical industry*—United States—Labor relations.
 9. *Pharmaceutical industry*—United States—Ethics.
 10. *Pharmaceutical industry*—United States—Innovation.
 11. *Pharmaceutical industry*—United States—Globalization.
 12. *Pharmaceutical industry*—United States—Patent law.
 13. *Pharmaceutical industry*—United States—Competition.
 14. *Pharmaceutical industry*—United States—Consumer protection.
 15. *Pharmaceutical industry*—United States—Public health.
 16. *Pharmaceutical industry*—United States—Biotechnology.
 17. *Pharmaceutical industry*—United States—Telemedicine.
 18. *Pharmaceutical industry*—United States—Artificial intelligence.
 19. *Pharmaceutical industry*—United States—Big data.
 20. *Pharmaceutical industry*—United States—Precision medicine.
 21. *Pharmaceutical industry*—United States—Personalized medicine.
 22. *Pharmaceutical industry*—United States—Regenerative medicine.
 23. *Pharmaceutical industry*—United States—Nanotechnology.
 24. *Pharmaceutical industry*—United States—Space exploration.
 25. *Pharmaceutical industry*—United States—Environmental health.
 26. *Pharmaceutical industry*—United States—Climate change.
 27. *Pharmaceutical industry*—United States—Pandemic preparedness.
 28. *Pharmaceutical industry*—United States—Vaccine development.
 29. *Pharmaceutical industry*—United States—Antibiotic resistance.
 30. *Pharmaceutical industry*—United States—Mental health.
 31. *Pharmaceutical industry*—United States—Geriatric care.
 32. *Pharmaceutical industry*—United States—Pediatric care.
 33. *Pharmaceutical industry*—United States—Oncology.
 34. *Pharmaceutical industry*—United States—Neurology.
 35. *Pharmaceutical industry*—United States—Cardiology.
 36. *Pharmaceutical industry*—United States—Endocrinology.
 37. *Pharmaceutical industry*—United States—Immunology.
 38. *Pharmaceutical industry*—United States—Infectious diseases.
 39. *Pharmaceutical industry*—United States—Rare diseases.
 40. *Pharmaceutical industry*—United States—Orphan drugs.
 41. *Pharmaceutical industry*—United States—Biologics.
 42. *Pharmaceutical industry*—United States—Small molecule drugs.
 43. *Pharmaceutical industry*—United States—Generics.
 44. *Pharmaceutical industry*—United States—Off-invention.
 45. *Pharmaceutical industry*—United States—Patent litigation.
 46. *Pharmaceutical industry*—United States—Settlements.
 47. *Pharmaceutical industry*—United States—Litigation costs.
 48. *Pharmaceutical industry*—United States—Discovery.
 49. *Pharmaceutical industry*—United States—Preclinical testing.
 50. *Pharmaceutical industry*—United States—Phase I trials.
 51. *Pharmaceutical industry*—United States—Phase II trials.
 52. *Pharmaceutical industry*—United States—Phase III trials.
 53. *Pharmaceutical industry*—United States—FDA approval.
 54. *Pharmaceutical industry*—United States—Post-market surveillance.
 55. *Pharmaceutical industry*—United States—Adverse events.
 56. *Pharmaceutical industry*—United States—Drug safety.
 57. *Pharmaceutical industry*—United States—Drug quality.
 58. *Pharmaceutical industry*—United States—Manufacturing.
 59. *Pharmaceutical industry*—United States—Supply chain.
 60. *Pharmaceutical industry*—United States—Distribution.
 61. *Pharmaceutical industry*—United States—Retail.
 62. *Pharmaceutical industry*—United States—Hospital formulary.
 63. *Pharmaceutical industry*—United States—Payers.
 64. *Pharmaceutical industry*—United States—Reimbursement.
 65. *Pharmaceutical industry*—United States—Net price.
 66. *Pharmaceutical industry*—United States—List price.
 67. *Pharmaceutical industry*—United States—Discounts.
 68. *Pharmaceutical industry*—United States—Promotional costs.
 69. *Pharmaceutical industry*—United States—Sales force.
 70. *Pharmaceutical industry*—United States—Medical representatives.
 71. *Pharmaceutical industry*—United States—Detailing.
 72. *Pharmaceutical industry*—United States—Sample distribution.
 73. *Pharmaceutical industry*—United States—Physician education.
 74. *Pharmaceutical industry*—United States—Continuing medical education.
 75. *Pharmaceutical industry*—United States—Medical journals.
 76. *Pharmaceutical industry*—United States—Medical conferences.
 77. *Pharmaceutical industry*—United States—Medical associations.
 78. *Pharmaceutical industry*—United States—Medical societies.
 79. *Pharmaceutical industry*—United States—Medical schools.
 80. *Pharmaceutical industry*—United States—Medical residents.
 81. *Pharmaceutical industry*—United States—Medical students.
 82. *Pharmaceutical industry*—United States—Medical research.
 83. *Pharmaceutical industry*—United States—Medical innovation.
 84. *Pharmaceutical industry*—United States—Medical progress.
 85. *Pharmaceutical industry*—United States—Medical excellence.
 86. *Pharmaceutical industry*—United States—Medical leadership.
 87. *Pharmaceutical industry*—United States—Medical vision.
 88. *Pharmaceutical industry*—United States—Medical future.
 89. *Pharmaceutical industry*—United States—Medical hope.
 90. *Pharmaceutical industry*—United States—Medical dream.
 91. *Pharmaceutical industry*—United States—Medical reality.
 92. *Pharmaceutical industry*—United States—Medical challenge.
 93. *Pharmaceutical industry*—United States—Medical opportunity.
 94. *Pharmaceutical industry*—United States—Medical responsibility.
 95. *Pharmaceutical industry*—United States—Medical commitment.
 96. *Pharmaceutical industry*—United States—Medical dedication.
 97. *Pharmaceutical industry*—United States—Medical passion.
 98. *Pharmaceutical industry*—United States—Medical love.
 99. *Pharmaceutical industry*—United States—Medical care.
 100. *Pharmaceutical industry*—United States—Medical service.
 101. *Pharmaceutical industry*—United States—Medical treatment.
 102. *Pharmaceutical industry*—United States—Medical intervention.
 103. *Pharmaceutical industry*—United States—Medical procedure.
 104. *Pharmaceutical industry*—United States—Medical operation.
 105. *Pharmaceutical industry*—United States—Medical surgery.
 106. *Pharmaceutical industry*—United States—Medical therapy.
 107. *Pharmaceutical industry*—United States—Medical management.
 108. *Pharmaceutical industry*—United States—Medical care plan.
 109. *Pharmaceutical industry*—United States—Medical treatment plan.
 110. *Pharmaceutical industry*—United States—Medical intervention plan.
 111. *Pharmaceutical industry*—United States—Medical procedure plan.
 112. *Pharmaceutical industry*—United States—Medical operation plan.
 113. *Pharmaceutical industry*—United States—Medical surgery plan.
 114. *Pharmaceutical industry*—United States—Medical therapy plan.
 115. *Pharmaceutical industry*—United States—Medical management plan.
 116. *Pharmaceutical industry*—United States—Medical care plan of action.
 117. *Pharmaceutical industry*—United States—Medical treatment plan of action.
 118. *Pharmaceutical industry*—United States—Medical intervention plan of action.
 119. *Pharmaceutical industry*—United States—Medical procedure plan of action.
 120. *Pharmaceutical industry*—United States—Medical operation plan of action.
 121. *Pharmaceutical industry*—United States—Medical surgery plan of action.
 122. *Pharmaceutical industry*—United States—Medical therapy plan of action.
 123. *Pharmaceutical industry*—United States—Medical management plan of action.
 124. *Pharmaceutical industry*—United States—Medical care plan of implementation.
 125. *Pharmaceutical industry*—United States—Medical treatment plan of implementation.
 126. *Pharmaceutical industry*—United States—Medical intervention plan of implementation.
 127. *Pharmaceutical industry*—United States—Medical procedure plan of implementation.
 128. *Pharmaceutical industry*—United States—Medical operation plan of implementation.
 129. *Pharmaceutical industry*—United States—Medical surgery plan of implementation.
 130. *Pharmaceutical industry*—United States—Medical therapy plan of implementation.
 131. *Pharmaceutical industry*—United States—Medical management plan of implementation.
 132. *Pharmaceutical industry*—United States—Medical care plan of evaluation.
 133. *Pharmaceutical industry*—United States—Medical treatment plan of evaluation.
 134. *Pharmaceutical industry*—United States—Medical intervention plan of evaluation.
 135. *Pharmaceutical industry*—United States—Medical procedure plan of evaluation.
 136. *Pharmaceutical industry*—United States—Medical operation plan of evaluation.
 137. *Pharmaceutical industry*—United States—Medical surgery plan of evaluation.
 138. *Pharmaceutical industry*—United States—Medical therapy plan of evaluation.
 139. *Pharmaceutical industry*—United States—Medical management plan of evaluation.
 140. *Pharmaceutical industry*—United States—Medical care plan of revision.
 141. *Pharmaceutical industry*—United States—Medical treatment plan of revision.
 142. *Pharmaceutical industry*—United States—Medical intervention plan of revision.
 143. *Pharmaceutical industry*—United States—Medical procedure plan of revision.
 144. *Pharmaceutical industry*—United States—Medical operation plan of revision.
 145. *Pharmaceutical industry*—United States—Medical surgery plan of revision.
 146. *Pharmaceutical industry*—United States—Medical therapy plan of revision.
 147. *Pharmaceutical industry*—United States—Medical management plan of revision.
 148. *Pharmaceutical industry*—United States—Medical care plan of improvement.
 149. *Pharmaceutical industry*—United States—Medical treatment plan of improvement.
 150. *Pharmaceutical industry*—United States—Medical intervention plan of improvement.
 151. *Pharmaceutical industry*—United States—Medical procedure plan of improvement.
 152. *Pharmaceutical industry*—United States—Medical operation plan of improvement.
 153. *Pharmaceutical industry*—United States—Medical surgery plan of improvement.
 154. *Pharmaceutical industry*—United States—Medical therapy plan of improvement.
 155. *Pharmaceutical industry*—United States—Medical management plan of improvement.
 156.

0 0 1

SATURDAY



AAWQ6M6J

A20

29/01/2022

#122

COMPANIES HOUSE

REPORT OF THE DIRECTORS

The directors present their annual report and the unaudited financial statements for the year ended 31 December 2020.

REVIEW OF DEVELOPMENTS AND BASIS OF PREPARATION OF THE ACCOUNTS

The Company has been dormant within the meaning of section 1169 of the Companies Act 2006 throughout the year. Key performance indicators are not therefore considered necessary for the understanding of the development, performance or position of the business of the Company.

On 15 March 2019, the Company's previous ultimate parent company and controlling party, Interserve Plc, entered administration. Immediately following the appointment of the administrators, substantially all of the business and assets and certain liabilities of Interserve Plc were sold to a newly incorporated company, Interserve Group Limited, controlled by the Group's lenders. On 15 March 2019, the entire issued share capital of the Company was transferred from Interserve Plc to Interserve Group Limited for nil consideration. Interserve Group Limited is now the company regarded by the directors of the Company to be the ultimate controlling party.

The Company does not receive financial support from either Interserve Group Limited, or any other Interserve Group company. The directors therefore intend to liquidate the Company. Accordingly, the directors have prepared the accounts on the basis that the Company is no longer a going concern, and all assets have been stated at the directors' best estimate of their net realisable value. The accounts do not reflect any future costs that may be incurred in liquidating the Company, as these were not committed to at the balance sheet date.

PROFIT AND LOSS ACCOUNT

No profit and loss account is presented with these financial statements because the Company has not received income, incurred expenditure or recognised any gains or losses during either the year under review or the preceding accounting period. There have been no movements in shareholders' funds during the year under review or the preceding accounting period.

DIRECTORS

The directors who served throughout the year are set out below:

Mr A J McDonald (resigned 2 February 2021)
Mr A K Smythe (resigned 30 July 2021)
Mr C J Edwards (appointed 3 February 2021)
Mr J M White (appointed 29 July 2021)


Neither of the directors had a material interest during the year in any significant contract with the Company or any Group undertaking.

AUDITORS

In accordance with section 480 of the Companies Act 2006, the Company, being dormant, is exempt from the obligation to appoint auditors as otherwise required by section 485 of that Act.

Capital Tower
91 Waterloo Road
London, SE1 8RT

Approved by the Board of Directors
and signed on behalf of the Board by



J M White
Director
27 January 2022

BALANCE SHEET AT 31 DECEMBER 2020


2020 2021 2022 2023

| | | 31 December
2020 | 31 December
2019 |
|---|---|---------------------|---------------------|
| | £ | | |
| CURRENT ASSETS | | | |
| Debtors | 4 | 643,943 | 643,943 |
| CREDITORS: amounts falling due within one year | 5 | (643,843) | (643,843) |
| NET CURRENT ASSETS | | 100 | 100 |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | 100 | 100 |
| CAPITAL AND RESERVES | | | |
| Called up share capital | 6 | 100,000 | 100 |
| EQUITY SHAREHOLDERS' FUNDS | | 100 | 100 |

- For the year ended 31 December 2020, the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 (the "2006 Act") relating to dormant companies.
- The members have not required the Company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the 2006 Act.
- The directors acknowledge their responsibility for:-
 - ensuring the Company keeps accounting records that comply with section 386 of the 2006 Act; and
 - preparing financial statements that give a true and fair view of the state of affairs of the Company as at the end of the financial year, and of its profit or loss for the financial year, in accordance with the requirements of sections 394 and 395 of the 2006 Act, and which otherwise comply with the requirements of the 2006 Act relating to financial statements, so far as applicable to the Company.

The financial statements of Tilbury Estates Limited, registered number 1107468 were approved by the Board of Directors and authorised for issue on 27 January 2022.

Signed on behalf of the Board of Directors.



J M White
Director

2020 2021 2022 2023

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2020

1. ACCOUNTING POLICIES

The financial statements have been prepared in accordance with applicable United Kingdom accounting standards. The particular accounting policies adopted are described below.

a) Convention

These financial statements have been prepared in accordance with the historical cost convention.

b) Going Concern

The Company has been dormant within the meaning of section 1169 of the Companies Act 2006 throughout the year.

The Company does not receive financial support from either Interserve Group Limited, or any other Interserve Group company. The directors therefore intend to liquidate the Company. Accordingly the directors have prepared the accounts on the basis that the Company is no longer a going concern, and all assets have been stated at the directors' best estimate of their net realisable value. The accounts do not reflect any future costs that may be incurred in liquidating the Company, as these were not committed to at the balance sheet date.

2. PROFIT AND LOSS ACCOUNT

No profit and loss account is presented with these financial statements because the Company has not received income, incurred expenditure or recognised any gains or losses during either the year under review or the preceding financial year. There have been no movements in shareholders' funds during the year under review or the preceding financial year.

3. DIRECTORS AND EMPLOYEES

No emoluments were payable to the directors of the Company, who were the only employees, during the current and preceding financial year.

4. DEBTORS

| | 2020
£ | 2019
£ |
|----------------------------------|-----------|-----------|
| Amount owed by fellow subsidiary | 643,943 | 643,943 |

5. CREDITORS: amounts falling due within one year

| | 2020
£ | 2019
£ |
|----------------------------------|-----------|-----------|
| Amount owed to fellow subsidiary | (643,843) | (643,843) |

6. CALLED UP SHARE CAPITAL

| | 2020
£ | 2019
£ |
|---|-----------|-----------|
| Authorised, allotted, called up and fully paid:
100 ordinary shares of £1 each | 100 | 100 |

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2020 (continued)

7. ULTIMATE PARENT UNDERTAKING AND RELATED PARTY TRANSACTIONS

The Company's immediate and ultimate parent company and controlling party, and parent company of the largest and smallest group which includes the Company and for which group financial statements are prepared, is Interserve Group Limited, a company incorporated in Great Britain.

The Company has taken advantage of the exemption contained in Financial Reporting Standard 8 "Related Party Disclosures" not to report transactions with other group companies.